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Abstract
1,5-Anhydro-D-fructose (AF) is a mono-saccharide directly formed from starch and glycogen by the action of a-1,4-
glucan lyase (EC 4.2.2.13). Our previous study has indicated that AF increases glucose tolerance and insulin secre-
tion in NMRI mice after administration through a gastric gavage in a single dose at 150 mg per mouse. In this
study, we used high-fat feeding of C57BL/6J mice to examine the influence of long-term administration of AF on
glucose-stimulated insulin secretion in vivo and in vitro. We found that 8-weeks of high-fat feeding increased body
weight, fasting blood glucose and insulin levels in C57BL/6J mice when compared to mice fed normal diet.
Impaired glucose tolerance was also observed in mice receiving 8-weeks of high-fat diet. In contrast, AF (1.5 g/kg/
day), administered through drinking water for 8-weeks, did not affect body weight or food and water intake in
mice fed either the high-fat or normal diet. There was no difference in basal blood glucose or insulin levels
between AF-treated and control group. Oral glucose tolerance test (OGTT) showed that AF did not affect glucose-
stimulated insulin secretion in mice. In in vitro studies with isolated islets, AF did not influence glucose-stimulated
insulin secretion in mice receiving either high-fat or normal diet. We therefore conclude that when given through
drinking water for 8 weeks at 1.5 g/kg/day, AF has no effect on glucose-stimulated insulin secretion in C57BL/6J
mice challenged with a high-fat diet.
Background
1,5-Anhydro-D-fructose (AF) is a mono-saccharide hav-
ing structural similarity to glucose [1]. It is produced by
the degradation of starch and glycogen catalysed by the
enzyme a-1,4-glucan lyase [1]. AF is present in fungi
and algae, including edible fungal and algal species [2,3],
as well as in mammalian tissues including rat liver [1,4].
In vitro studies have indicated that enzymatic oxidation
of 1,5-anhydro-D-glucitol (AG) by fungal pyranose
2-oxidases results in the formation of AF; however, this
reaction has not been demonstrated in vivo in mammals
[5]. In mammals, the further metabolism of AF involves
a NADPH-dependent specific reductase that reduces AF
to AG [1,6]. It has been reported that AG, the second
most abundant polyol after glucose in human fluid, sti-
mulated insulin secretion in two rodent insulinoma cell
lines studied, i.e., rat RINr and mouse MIN6 at
physiological relevant concentrations [7]. In fungi and
red algae AF is metabolised to secondary metabolites
such as microthecin, ascopyrones and echinosporin
[2,3,8,9]. However, the importance of AF in mammalian
physiology remains elusive. The works by Hisaku et al.
[10], Fujisie et al. [11] and Yamaji et al. [12] have indi-
cated that AF has antioxidant and antimicrobial effects,
suggesting a potential biological role for AF in mam-
mals. Furthermore, we have previously shown that when
given through a gastric gavage (150 mg) together with
glucose (150 mg/mouse), AF induces glucose tolerance,
insulin secretion and increases in plasma levels of gluca-
gon-like peptide-1 (GLP-1) [13]. The effect of AF on
glucose tolerance, however, was not detected when
administered intravenously [13]. Based on these observa-
tions, the role of AF in increasing endogenous GLP-1
secretion needs to be explored further to clarify the dis-
crepancy. In the current study, we used high-fat feeding
of C57BL/6J mice as a model to investigate the effect of
long-term administration of AF on glucose-stimulated
insulin secretion in vivo and in vitro. C57BL/6J mice are
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any medium, provided the original work is properly cited.susceptible to high-fat diet and develop glucose intoler-
ance more readily than other strains [14]. Furthermore
as indicated above, as AF metabolism is an energy-
consuming process due to the use of NADPH in its
reduction to AG [1,6], feeding mice with AF might
reduce the extent for obesity development.
Methods
Animal
Four-week old female C57BL/6J mice weighing 15 g
were obtained from Bomholtgaard Breeding and
Research Center, Denmark. Animals were housed on a
12-h light/dark cycle with ad libitum access to diets and
water. The mice were fed with either a standard rodent
food or a high-fat diet (#D12310 and #D12309; Research
Diets, New Brunswick, NJ). The normal diet had a calo-
ric density of 12.6 kJ/g and contained 25.8% protein,
62.8% carbohydrates and 11.4% fat. The high-fat diet
consisted of 16.4% protein, 25.6% carbohydrates and
58.0% fat with a caloric density of 23.6 kJ/g. The mice
remained on each of the diets for 8 weeks. During the 8
weeks, AF (1.5 g/kg/day) dissolved in tap water was
made accessible to the mice. The control group received
tap water. The food and water intake and body weight
were recorded weekly.
Oral glucose tolerance test
After 8 weeks of AF treatment, blood was drawn from
the intra-orbital bullar plexus of all mice for the mea-
surement of basal glucose and insulin levels. For oral
glucose tolerance test (OGTT), mice fasting overnight
were given glucose (150 mg/mouse) orally and their
blood was collected at times 0, 15, 30, 60, 90 and 120
min following glucose administration. All procedures
using animals were approved by the local Ethics Com-
mittee and followed the guidelines for experimentation
in animals (European Economic Community Council
Directive 86/609/EEC).
Insulin secretion in vitro
Pancreatic islets were isolated from mice using the col-
lagenase isolation technique. Briefly, the common bile
duct was ligated at the papilla vateri and cannulated
after a midline incision. The pancreas was filled with 3
ml of ice-cold Hank’s balanced salts (HBSS) supplemen-
ted with 0.4 mg/ml collagenase P (Roche Molecular
Biochemicals, Mannheim, Germany) before removal and
then incubated at 37°C for 19 min. After washing the
incubated islets for three times with HBSS, they were
handpicked under a stereomicroscope and incubated
overnight in RPMI 1640 medium supplemented with
10% fetal bovine serum, 2.05 mmol/l L-glutamine, 2.5
μg/ml amphotericin B, 100 IU/ml penicillin and 100 μg/
ml streptomycin at 37°C in humidified air equilibrated
with 5% CO2. After overnight incubation, the islets
were washed three times and then pre-incubated for 60
min at 37°C in a Hepes medium (pH 7.4 supplemented
with 0.1% human serum albumin (Sigma) and 3.3
mmol/l glucose. The Hepes medium consisted of
125 mmol/l NaCl, 5.9 mmol/l KCl, 1.2 mmol/l MgCl2,
1.28 mmol/l CaCl2 and 25 mmol/l Hepes. After pre-
incubation, groups of three islets were transferred into
separate chambers containing 200 μlo ft h eH e p e so r
RPMI medium supplemented with glucose at various
concentrations. Following incubation at 37°C for 60
min, 25 μl of the medium was collected and stored at
-20°C until analysis.
Analysis of insulin and glucose
Insulin was determined using guinea pig anti-rat insulin,
125I-labeled human insulin, and rat insulin standard
(Linco Research Inc, St Charles, MO) by RadioImmu-
noAssay (RIA). Plasma glucose was determined by the
glucose oxidase method.
Statistics
Mean values ± SE for glucose and insulin plasma levels
are shown. Statistical comparisons for differences
between AF and control were performed by unpaired
Student t test.
Results
AF treatment for 8 weeks
As seen in Table 1, 8 weeks of high-fat feeding
increased body weight and blood glucose compared with
t h em i c ef e dn o r m a ld i e t .B yc o n t r a s t ,A Fd i dn o t
Table 1 Body weight, food intake and water intake in
C57BL/6J mice treated with AF for 8 weeks.
High-fat diet Normal diet
(8 weeks) (8 weeks)
Body weight (g)
Control 28 ± 1.0 21.2 ± 0.1*
AF 30.4 ±1.3 21 ± 0.2*
Food intake (g)
Control 2.1 ± 0.05 2.5 ± 0.07
AF 2.2 ± 0.29 2.6 ± 0.04
Water Intake (ml)
Control 3.4 ± 0.8 3.1 ± 0.9
AF 3.8 ± 0.9 3.5 ± 1.0
Glucose (mmol/l)
Control 7.4 ± 0.3 5.4 ± 0.4*
AF 7.8 ± 0.4 5.3 ± 0.3*
Insulin (pmol/l)
Control 211 ± 22 129 ± 26*
AF 302 ± 34 113 ± 30*
Data are means ± SE (n = 12). Student’s t test, *p < 0.05 between high-fat
diet and normal diet.
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levels in mice fed high-fat diet. There was no difference
in the food and water intake levels between AF-treated
and control group of mice fed high-fat diet. In mice fed
normal diet, AF did not affect body weight, food and
water intake, or fasting blood levels for glucose and
insulin (Table 1).
Oral glucose tolerance test (OGTT)
After 8 weeks of high-fat or normal diet, oral glucose
tolerance test was performed in mice treated with or
without AF. As shown in Figure 1, the AUC insulin dur-
ing the 90 min study period in high-fat fed mice was
decreased compared with mice fed normal diet (128 ±
26 vs. 275 ± 41 nmol/l). However, AF treatment had no
effect on impaired glucose tolerance induced by high-fat
feeding (Figure 2a and 2c). AF did not affect and/or
increase glucose tolerance in mice fed normal diet (Fig-
ure 2b and 2d).
Islet studies
Insulin secretion over a wide range of glucose concentra-
tions was similar in isolated islets from control and AF-
treated high-fat-fed mice (Figure 3). Similar results were
also observed in isolated islets from normal diet-fed mice
after 8 weeks of treatment with AF (data not shown).
Discussion
Our previous results demonstrated that AF increased
glucose tolerance and insulin secretion in NMRI mice
Figure 1 Islet hormone secretion in vivo.T h eA U Cinsulin for 90
min is calculated after oral glucose tolerance test. HF, in high-fat
diet, NF, in normal diet. Data are means ± SE (n = 12).
Figure 2 Oral glucose tolerance test (OGTT) in C57BL/6J mice treated with AF for 8 weeks in high-fat diet and in normal diet.
Overnight-fasted mice were administrated 1.0 g/kg glucose by a gastric gavage. Blood samples were taken at 0, 15, 30, 60, 90 and 120 min.
Plasma levels of insulin (a, b) and glucose (c, d) were measured. Data are means ± SE (n = 12).
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single high dose of 75 or 150 mg per mouse. Further-
more, in these mice, AF enhanced the increase in
plasma levels of the gut hormone, GLP-1. In the present
study, we examined whether long-term administration
of AF at a more moderately high dose influences glu-
cose-stimulated insulin sec r e t i o ni nC 5 7 B L / 6 Jm i c e .
C57BL/6J mice have been shown to be susceptible to
developing glucose intolerance more readily than other
s t r a i n sw h e nm a i n t a i n e do nah i g h - f a td i e t[ 1 4 - 1 6 ]a n d
were the selected model in the current study.
It was observed that AF did not influence glucose tol-
erance and insulin secretion in C57BL/6J mice fed a
high-fat diet (Figure 1, 2, 3). In this study, AF was admi-
nistered to the mice, fed either a high-fat or normal diet
for 8 weeks, via drinking water. The dose of AF was 1.5
g/kg/day, or around 30 mg/mouse/day. This dose is
much lower than the one used in our earlier single and
high dose study [13]. It would be possible that the cur-
rent dose of 30 mg/mouse/day was not sufficient to
change glucose tolerance and insulin secretion. How-
ever, high dose of AF, which might have an effect, may
not have practical application either as a drug or a
health food additive. Beside the different mouse models
and the high dose used [13], the routes of administra-
tion of AF were also different in these two studies. In
the previous study [13], AF was given through a gastric
gavage tube placed in the stomach of the mice, while
AF was administered through drinking water in the pre-
sent study. It is not sure if these might have influenced
the effective concentration of AF in the circulating
blood, which may be important for the biological activ-
ity of AF. On the other hand, if the major in vivo
physiological function of AF is by its antioxidant activity
[12], it might not improve glucose tolerance under these
conditions since it has been reported that high fat does
not cause oxidative stress [17]. It is also known that
fatty acids acutely amplify glucose-induced insulin secre-
tion from the pancreatic b-cell, but they become harm-
ful when present at elevated levels for prolonged periods
of time due to their deleterious effects on b-cell func-
tion including inhibition of insulin secretion, the so-
called lipotoxicity [17]. That is, the possible positive
effect of AF on glucose tolerance might have been
blunted due to high-fat diet feeding. A high-fat diet has
been shown to induce hyperglycemia, hyperinsulinemia,
hyperlipidemia, obesity and glucose intolerance in
C57BL/6J mice (Table 1) [15,16,18]. Thus, an additional
drug might be needed together with AF in order to
overcome the strong changes in pathophysiology in
C57BL/6J mice challenged with a high-fat diet compared
t oa c u t ea d m i n i s t r a t i o no fas i n g l eh i g hd o s eo fA Fi n
normal NMRI mice [13]. It should be noted also that
though AF is energy-negative feeding mice at 1.5 g/kg/
day apparently did not affect the weight gain (Table 1).
AF has recently been reported to have several health
beneficial effects including anti-inflammatory and anti-
cancer effects [19-21] beside its antioxidant effect [12].
Though no indication of improved glucose tolerance
was evident, this study further confirmed our early
observations [22,23] that AF is a safe sugar to consume
as no adverse effect was observed in the current study.
Conclusions
With C57BL/6J mice as model which is liable to develop
glucose intolerance when fed on a high-fat diet, 1,5-
Anhydro-D-fructose (AF) at 1.5 g/kg/day, administered
through drinking water for 8-weeks, did not affect body
weight gain or food and water intake fed on either high-
fat or normal diet. No difference in basal blood glucose
or insulin levels between AF-treated and control group
was found. These indicate that AF as a food antioxidant
does not apparently interfere with sugar metabolism in
mice.
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